Bioanalysis, ADME and biomarkers at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

34 organizations at ACT 2026 present work in bioanalysis, ADME and biomarkers: 29 service, testing and tools companies, 4 drug developers and 1 university, agency or non-profit. Between them they bring 58 presentations to the program. Most represented: Labcorp (12 on the program), Novartis (6 on the program), Altasciences (5 on the program). As of Oct 8, 2026.

All 231 organizations at ACT 2026 →

Showing 1–7 of 34 organizations

Organization	ACT 2026 Attendance
Labcorp Burlington, NC
labcorp.com Contract research organizations (CROs) Laboratory services company whose drug development arm runs nonclinical toxicology, pathology and safety studies for drug and chemical developers.	Booth Exhibiting at Booth 310 Mon, Nov 169:30am–6:30pmTue, Nov 178:00am–4:30pm Session Sun Nov 15 1:00pm–4:30pm Beyond Animal Models: Navigating New Approach Methodologies in Modern Drug Development with Case Study Examples (CE5) New approach methods · with U.S. Food and Drug Administration 1:00pmIntroduction (CE5-1)U.S. Food and Drug Administration 1:05pmFDA's 2025 Roadmap to Reduce Animal Testing: Leveraging NAMs to Address Preclinical Safety (CE5-2)U.S. Food and Drug Administration 1:30pmNew Approach Methodologies (NAMs): Role of Nonclinical Scientists (CE5-3)Gilead Sciences 2:00pmComplex Human-Derived Models as New Approach Methodologies (NAMs) for Drug Discovery and Development (CE5-4)Sanofi 3:00pmNew Approach Methodologies in Practice: Creating Virtual Control Groups for Nonclinical Studies (CE5-5)Labcorp 3:30pmNAMs Adoption in a Global Drug Development Laboratory (CE5-6)Labcorp Talk Sun Nov 15 3:00pm–3:30pm Part of Beyond Animal Models: Navigating New Approach Methodologies in Modern Drug Development with Case Study Examples (CE5) New Approach Methodologies in Practice: Creating Virtual Control Groups for Nonclinical Studies (CE5-5) Study data · New approach methods Talk Sun Nov 15 3:30pm–4:00pm Part of Beyond Animal Models: Navigating New Approach Methodologies in Modern Drug Development with Case Study Examples (CE5) NAMs Adoption in a Global Drug Development Laboratory (CE5-6) New approach methods Session Mon Nov 16 9:00am–12:00pm Beyond the Vessel Wall: Translational Insights into Vascular Inflammation (S03) Pathology · Translational safety · with Korsana Biosciences 9:00amIntroduction to Vascular Inflammation (S03-1)Korsana Biosciences 9:15amDrug Induced Vascular Injury (DIVI) Related to Biologic Therapies: Mechanisms and Sensitivity (S03-2)International Academy of Toxicologic Pathology 9:45amA Regulatory Perspective (S03-3)ToxStrategies 10:45amBiomarkers of Vascular Injury (S03-4)Merck 11:15amInnovative Tools and Future Directions (S03-5)Kymera Therapeutics Poster Mon Nov 16 5:00pm–6:30pm Applying a Virtual Control Group Retrospectively to a 26-Week Subcutaneous Repeat Dose Toxicity Study in the Cynomolgus Monkey (P508) Nelson Exhibit Ballroom · Poster P508 Study data Poster Mon Nov 16 5:00pm–6:30pm Assessment of a Functional Observational Battery in Minipigs across Multiple Research Sites (P117) Nelson Exhibit Ballroom · Poster P117 Safety pharmacology · Animal models Poster Mon Nov 16 5:00pm–6:30pm Development of an Integration Site Analysis Assay in AAV2 and AAV9 Administered Murine Models (P301) Nelson Exhibit Ballroom · Poster P301 Biologics and new modalities · Genetic toxicology Poster Mon Nov 16 5:00pm–6:30pm Enabling Flexible yet Comparable Cell Counting Strategies in Cell and Gene Product Development: A Comparative Evaluation of Automated Platforms (P206) Nelson Exhibit Ballroom · Poster P206 Biologics and new modalities · Bioanalysis and biomarkers Poster Mon Nov 16 5:00pm–6:30pm Evaluation of Wild Type and Humanized IgG1/4 Göttingen Minipigs for Subchronic Toxicology Assessment of Biotherapeutics (P127) Nelson Exhibit Ballroom · Poster P127 Animal models · Biologics and new modalities Poster Mon Nov 16 5:00pm–6:30pm Feasibility of a Paddling Pool Test (PPT) as an Alternative Assessment to the Morris Water Maze (MWM) in Mice (P517) Nelson Exhibit Ballroom · Poster P517 Neurotoxicology Poster Mon Nov 16 5:00pm–6:30pm MRI-Guided Targeted Delivery of AAV9 to the Putamen of Nonhuman Primates and Göttingen Minipigs: A Translational Framework for CNS Gene and Cell Therapies (P302) Nelson Exhibit Ballroom · Poster P302 Biologics and new modalities · Neurotoxicology Poster Mon Nov 16 5:00pm–6:30pm Nonhuman Primate Species Considerations for Preclinical Gene Therapy Studies (P132) Nelson Exhibit Ballroom · Poster P132 Animal models · Biologics and new modalities Poster Mon Nov 16 5:00pm–6:30pm Pulmonary Embolism of Marrow Tissue Secondary to Bone Marrow Aspiration for Immunophenotyping in Cynomolgus Monkeys (P136) Nelson Exhibit Ballroom · Poster P136 Pathology · Animal models Poster Mon Nov 16 5:00pm–6:30pm Validation of the Cincinnati Water Maze for Egocentric Learning and Memory in Developmental Neurotoxicity Studies (P530) Nelson Exhibit Ballroom · Poster P530 Neurotoxicology · DART Talk Tue Nov 17 8:00am–8:55am Beyond the Roadmaps: Applying Human-Relevant NAMs to Weight-of-Evidence Assessments Grand Oaks Ballroom Q New approach methods · Regulatory
Novartis Basel, Switzerland
novartis.com Pharmaceutical companies Swiss pharmaceutical company; its preclinical safety teams present on first-in-human dosing, oligonucleotides, minipig lactation studies and excipient safety.	Session Sun Nov 15 8:00am–11:30am First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Translational safety · with Boehringer Ingelheim 8:00amFoundational Approaches to FIH Dose Selection (CE1-1)White Oak Regulatory Tox 8:20amModel-Informed Approaches to FIH Dose Prediction (CE1-2)Bedard ADME-Tox Solutions, Tango Therapeutics 8:45amCNS-Delivered Therapeutics: Anatomic, Physiologic, and Modality-Specific Considerations (CE1-3)Akkeri 9:10amInter-Species Dose Extrapolation for Ocular Therapeutics: Translational Frameworks for Eye-Delivered Products (CE1-4)Novartis 10:00amCrossing the Species Divide in Inhaled Dosing (CE1-5)Novartis 10:25amInteractive Session: Hypothetical Challenge Scenarios in FIH Setting (CE1-6)Boehringer Ingelheim Talk Sun Nov 15 9:10am–9:30am Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Inter-Species Dose Extrapolation for Ocular Therapeutics: Translational Frameworks for Eye-Delivered Products (CE1-4) Translational safety Talk Sun Nov 15 10:00am–10:25am Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Crossing the Species Divide in Inhaled Dosing (CE1-5) Inhalation toxicology · Translational safety Poster Mon Nov 16 5:00pm–6:30pm Coadministration of Two GalNAc-Conjugated siRNAs in Rats Produces Nonadverse Effects Similar to the Findings of the Individual siRNAs in General Toxicology Studies (P405) Nelson Exhibit Ballroom · Poster P405 Biologics and new modalities Poster Mon Nov 16 5:00pm–6:30pm Comparison between the Intravenous (IV) and Subcutaneous (SC) Routes of Administration of Inclisiran on Pharmacodynamics (PD), Toxicokinetics (TK) and Safety in the Nonhuman Primate (P409) Nelson Exhibit Ballroom · Poster P409 Biologics and new modalities · Bioanalysis and biomarkers Poster Mon Nov 16 5:00pm–6:30pm Neonatal Excipient Safety: Risk Assessment Considerations for Ethyl Benzoate in a Vulnerable Patient Population (P427) Nelson Exhibit Ballroom · Poster P427 Chemical risk assessment Poster Mon Nov 16 5:00pm–6:30pm The Göttingen Minipig as a Preclinical Model of Drug Transfer during Lactation (P440) Nelson Exhibit Ballroom · Poster P440 DART · Animal models Talk Wed Nov 18 2:05pm–2:30pm Part of Hot Topics (S18) Cross-Industry Survey of Nonclinical Development Strategies for Oligonucleotide Therapeutics: Species Selection, Dose Setting, and Translational Approaches (S18-2) Biologics and new modalities · Animal models
Altasciences Laval, QC, Canada	◆Diamond Supporter
altasciences.com Contract research organizations (CROs)Diamond Supporter Drug development organization combining nonclinical studies, bioanalysis, early clinical trials, formulation and manufacturing for early-phase programs.	Booth Exhibiting at Booth 304 Mon, Nov 169:30am–6:30pmTue, Nov 178:00am–4:30pm Talk Sun Nov 15 12:00pm–12:55pm Genetic and Biomarker Consistency in Southeast Asian Cynomolgus Monkeys for Preclinical Research Grand Oaks Ballroom N Animal models Poster Mon Nov 16 5:00pm–6:30pm Addressing the Data Gap: Sampling Feasibility and Effects on Clinical Pathology Results after Liver Biopsy in Nonhuman Primates (P115) Nelson Exhibit Ballroom · Poster P115 Pathology · Animal models Poster Mon Nov 16 5:00pm–6:30pm An Internal Study in Sinclair Nanopig® Miniature Swine to Generate Background Data and Reference Ranges (P116) Nelson Exhibit Ballroom · Poster P116 Animal models · Study data Poster Mon Nov 16 5:00pm–6:30pm Pharmacokinetic Studies of Long-Acting Transdermal Buprenorphine in Miniature Swine and Canine (P430) Nelson Exhibit Ballroom · Poster P430 Bioanalysis and biomarkers · Animal models Poster Mon Nov 16 5:00pm–6:30pm Species Divergence in Toxicity Profiling of Lipid Nanoparticle-Oligonucleotide Therapeutics: An Adverse Outcome Pathway-Based Comparison in Rodent and Nonhuman Primate (P439) Nelson Exhibit Ballroom · Poster P439 Biologics and new modalities · Animal models Talk Tue Nov 17 11:15am–11:45am Part of Overcoming the Blood-Brain Barrier and Translational Challenges in the Nonclinical Development of CNS Drugs (S08) Toxicology Challenges and Opportunities for Gene Therapy: CNS-Related Assessment in Animal Models (S08-6) Biologics and new modalities · Neurotoxicology
SAFE Pharmaceutical Services Great Falls, VA
safecro.com Contract research organizations (CROs) Contract research organization with GLP, AAALAC-accredited toxicology facilities across China and its own primate breeding colony, plus a US advisory team.	Booth Exhibiting at Booth 717 Mon, Nov 169:30am–6:30pmTue, Nov 178:00am–4:30pm Poster Mon Nov 16 5:00pm–6:30pm Comparative Toxicity and Pharmacokinetic Profile of Oligonucleotide Therapeutics in Cynomolgus Monkeys (P408) Nelson Exhibit Ballroom · Poster P408 Biologics and new modalities · Bioanalysis and biomarkers Poster Mon Nov 16 5:00pm–6:30pm Experimental Design and Outcome Analysis for Preclinical Dependence Assessment of α₂δ Subunit Ligands of Voltage-Gated Calcium Channels (P416) Nelson Exhibit Ballroom · Poster P416 Safety pharmacology Poster Mon Nov 16 5:00pm–6:30pm ICH S11-Compliant Juvenile NHP Studies: A Retrospective Analysis of 12 Toxicology Studies Supporting Pediatric Drug Development (P422) Nelson Exhibit Ballroom · Poster P422 DART · Animal models Poster Mon Nov 16 5:00pm–6:30pm Repeated Dose Toxicity and Toxicokinetic Study of Inhaled Powder X-101 in Mice (P448) Nelson Exhibit Ballroom · Poster P448 Inhalation toxicology
TriApex Nanjing, China	◆Platinum Supporter
tri-apex.com Contract research organizations (CROs)Platinum Supporter Chinese nonclinical and clinical CRO with NMPA GLP certification, presenting work on ADCs, oligonucleotides, siRNA and gene therapy.	Talk Mon Nov 16 7:00am–7:55am Context-Driven Tiered and Integrated Nonclinical Evaluation: From Framework to ADC Nonclinical Implementation Grand Oaks Ballroom O Biologics and new modalities · Regulatory Poster Mon Nov 16 5:00pm–6:30pm A Tiered Strategy for Evaluating In Vivo Complement Activation Risk of Chemically-Modified ASOs in Nonclinical Studies (P505) Nelson Exhibit Ballroom · Poster P505 Immunotoxicology · Biologics and new modalities Poster Mon Nov 16 5:00pm–6:30pm Biodistribution and Neurotoxicity Assessment of rAAV1 Gene Therapy after Round Window Membrane Injection (P120) Nelson Exhibit Ballroom · Poster P120 Biologics and new modalities · Neurotoxicology Poster Mon Nov 16 5:00pm–6:30pm Toxicokinetic Characteristics and Toxicity Findings of Lipid-Delivered Small Interfering RNA Drugs in Cynomolgus Studies (P139) Nelson Exhibit Ballroom · Poster P139 Biologics and new modalities · Bioanalysis and biomarkers
Nomic Bio Montreal, QC, Canada
nomic.bio Specialist testing laboratories Montreal proteomics company running high-throughput protein profiling with its nELISA technology, used here to read toxicity markers from in vitro models.	Poster Mon Nov 16 5:00pm–6:30pm Beyond LDH: High-Throughput Proteomics Capture Model- and MOA-Specific Markers of Toxicity and Bioactivity for In Vitro Safety Assessment (P403) Nelson Exhibit Ballroom · Poster P403 Bioanalysis and biomarkers · New approach methods Poster Mon Nov 16 5:00pm–6:30pm Interpreting Complex In Vitro Models Using High-Throughput Proteomics: Insights from Quantifying 1000 Proteins in the Conditioned Media of Organoids and Tissue Slices (P520) Nelson Exhibit Ballroom · Poster P520 Bioanalysis and biomarkers · New approach methods Poster Mon Nov 16 5:00pm–6:30pm Liver Toxicity across In Vitro and In Vivo Models: High-Throughput Protein Profiling Captures Distinct Mechanisms of Toxicity and Predicts Clinical Hepatotoxicity (P425) Nelson Exhibit Ballroom · Poster P425 Bioanalysis and biomarkers · New approach methods
Merck Rahway, NJ	◆Gold Supporter
merck.com Pharmaceutical companiesGold Supporter US-based global pharmaceutical company, known as MSD outside the US and Canada, making prescription medicines and vaccines.	Talk Mon Nov 16 10:45am–11:15am Part of Beyond the Vessel Wall: Translational Insights into Vascular Inflammation (S03) Biomarkers of Vascular Injury (S03-4) Bioanalysis and biomarkers Poster Mon Nov 16 5:00pm–6:30pm Evaluation of In Vitro Kidney Models to Investigate the Role of Megalin-Mediated Transport in Drug-Induced Kidney Injury (P516) Nelson Exhibit Ballroom · Poster P516 New approach methods

Instantly find 20 buyers in bioanalysis, ADME and biomarkers

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction

Instantly find 20 buyers in bioanalysis, ADME and biomarkers

Browse ACT 2026 by